LENZ insider filings
LENZ Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-03. Screen LENZ transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 1 filing by 4 insiders — 2,718,684 shares, $9,134,778 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 1.
- Largest priced transaction: sale of 2,159,516 shares @ $3.36 ($7,255,974) by RA CAPITAL MANAGEMENT, L.P., filed 2026-11-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. — 10% owner & RA Capital Healthcare Fund LP — 10% owner & Kolchinsky Peter — 10% owner & Shah Rajeev M. — 10% owner | 1 | — | 3 legs · 2,718,684 sh · $9,134,778 | — |
| Chevallard Daniel R. — Chief Financial Officer | 1 | — | — | 1 |
Recent insider filings — LENZ Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-03 | 4 | Chevallard Daniel R. — Chief Financial Officer | Grant/award (A): 652,063 (derivative) @ $0 | EDGAR |
| 2026-11-02 | 4 | RA CAPITAL MANAGEMENT, L.P. — 10% owner RA Capital Healthcare Fund LP — 10% owner Kolchinsky Peter — 10% owner Shah Rajeev M. — 10% owner | Sale (S): 2,159,516 @ $3.36 · Sale (S): 451,998 @ $3.36 · Sale (S): 107,170 @ $3.36 | EDGAR |
| 2026-06-15 | 4 | Guerard Frederic — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Scheiner Zachary — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | George Jeffrey P. — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Thunen Shelley B — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | MCCOLLUM JAMES W — Director | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-03-30 | 4 | George Jeffrey P. — Director | Purchase (P): 5,592 @ $8.92 | EDGAR |
| 2026-03-30 | 4 | Schimmelpennink Evert B. — President, CEO and Secretary, Director | Purchase (P): 28,089 @ $8.95 | EDGAR |
| 2026-03-30 | 4 | Chevallard Daniel R. — Chief Financial Officer | Purchase (P): 7,500 @ $8.57 | EDGAR |
| 2026-01-06 | 4 | Odrich Marc — Chief Medical Officer | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Olsson Shawn — Chief Commercial Officer | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Schimmelpennink Evert B. — President, CEO and Secretary, Director | Grant/award (A): 358,100 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Chevallard Daniel R. — Chief Financial Officer | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Olsson Shawn — Chief Commercial Officer | Option exercise (M): 10,000 @ $2.08 · Sale (S): 4,212 @ $25.74 · Sale (S): 5,788 @ $26.37 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | MCCOLLUM JAMES W — Director | Purchase (P): 10,500 @ $22.79 | EDGAR |
| 2025-11-07 | 4 | Chevallard Daniel R. — Chief Financial Officer | Purchase (P): 20 @ $22.71 · Purchase (P): 2,178 @ $22.76 | EDGAR |
| 2025-10-02 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 49,701 @ $45.35 · Sale (S): 34,405 @ $45.35 · Sale (S): 83,066 @ $46.41 · Sale (S): 57,502 @ $46.41 · Sale (S): 177 @ $47.01 · Sale (S): 123 @ $47.01 | EDGAR |
| 2025-09-22 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 49,479 @ $41.59 · Sale (S): 24,370 @ $41.59 · Sale (S): 40,907 @ $43.00 · Sale (S): 20,148 @ $43.00 · Sale (S): 268 @ $43.30 · Sale (S): 132 @ $43.30 | EDGAR |
| 2025-08-26 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 20,493 @ $40.03 · Sale (S): 10,076 @ $40.03 · Sale (S): 5,668 @ $40.59 · Sale (S): 2,809 @ $40.59 · Sale (S): 50,270 @ $39.53 · Sale (S): 24,760 @ $39.53 · +6 more | EDGAR |
| 2025-08-19 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 145,051 @ $39.50 · Sale (S): 69,949 @ $39.50 · Sale (S): 30,628 @ $38.56 · Sale (S): 15,085 @ $38.56 | EDGAR |
| 2025-07-14 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 191,376 @ $34 | EDGAR |
| 2025-07-01 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 200,000 @ $30.46 | EDGAR |
| 2025-06-20 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 100,000 @ $29.95 · Sale (S): 100,877 @ $30.35 · Sale (S): 133,924 @ $30.25 | EDGAR |
| 2025-06-12 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Sale (S): 350,000 @ $29 | EDGAR |
| 2025-06-11 | 4 | Guerard Frederic — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Scheiner Zachary — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | George Jeffrey P. — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Thunen Shelley B — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | MCCOLLUM JAMES W — Director | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-04-09 | 4 | Olsson Shawn — Chief Commercial Officer | Option exercise (M): 1,400 @ $2.08 · Option exercise (M): 1,400 (derivative) @ $0 | EDGAR |
| 2025-03-07 | 4 | Schimmelpennink Evert B. — President, CEO and Secretary, Director | Option exercise (M): 4,200 @ $1.04 · Option exercise (M): 4,200 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | Olsson Shawn — Chief Commercial Officer | Option exercise (M): 3,333 @ $2.08 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2024-07-23 | 4 | Schimmelpennink Evert B. — President, CEO and Secretary, Director | Option exercise (M): 45,000 @ $1.04 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2024-05-15 | 4 | Chevallard Daniel R. — Chief Financial Officer | Purchase (P): 3,188 @ $15.68 | EDGAR |
| 2024-05-14 | 4 | MCCOLLUM JAMES W — Director | Purchase (P): 31,332 @ $15.99 | EDGAR |
| 2024-03-25 | 4 | Odrich Marc — Chief Medical Officer | Grant/award (A): 99,599 @ $0 · Grant/award (A): 66,472 (derivative) @ $0 · Grant/award (A): 105,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Scheiner Zachary — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | George Jeffrey P. — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Schimmelpennink Evert B. — President, CEO and Secretary, Director | Grant/award (A): 387,106 (derivative) @ $0 · Grant/award (A): 82,723 (derivative) @ $0 · Grant/award (A): 315,864 (derivative) @ $0 · Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Chevallard Daniel R. — Chief Financial Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Versant Venture Capital VI, L.P. — 10% owner Versant Ventures VI GP, L.P. — 10% owner Versant Ventures VI GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner | Other (J): 598,203 | EDGAR |
| 2024-03-25 | 4 | Drapkin Kimberlee C — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner RA Capital Healthcare Fund LP — Director, 10% owner RA Capital Nexus Fund II, L.P. — Director, 10% owner Kolchinsky Peter — Director, 10% owner Shah Rajeev M. — Director, 10% owner | Grant/award (A): 2,386,301 · Grant/award (A): 694,755 · Grant/award (A): 164,729 · Purchase (P): 933,038 @ $15.03 · Purchase (P): 64,971 @ $15.03 · Grant/award (A): 54,582 (derivative) · +3 more | EDGAR |
| 2024-03-25 | 4 | Thunen Shelley B — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | MCCOLLUM JAMES W — Director | Grant/award (A): 95,034 @ $0 · Grant/award (A): 477,600 @ $0 · Grant/award (A): 16,633 @ $15.03 · Grant/award (A): 6,575 (derivative) @ $0 · Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — LENZ Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-08 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LENZ returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs